New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients

Core Insights - Teleflex Incorporated announced findings from a multinational study demonstrating the efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs) in reducing central line-associated bloodstream infections (CLABSIs) by 70.5% [2][3][4] Study Findings - The study involved over 6,670 patients from 12 Intensive Care Units across eight countries, including India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey [1] - Patients using chlorhexidine-impregnated CVCs had a significantly lower incidence of infections caused by various pathogens, including gram-negative and gram-positive bacteria, as well as fungi [4][7] - The study highlighted that unprotected CVCs may pose an independent risk factor for CLABSI compared to chlorhexidine-impregnated CVCs, even with adherence to best practices [3][7] Implications for Teleflex - The results reinforce Teleflex's claims regarding the effectiveness of its Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens [4] - The company aims to enhance healthcare quality through innovative medical technologies, positioning itself as a trusted partner in the healthcare sector [5][6]